NCT05055258 - A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

October 27, 2022

Study Completion Date

October 27, 2022

Conditions

Angioedema, Hereditary, Types I and II

Interventions

DRUG

KVD824

KVD824 300 mg Modified-Release Tablets

DRUG

Placebo to KVD824

Placebo to KVD824 300 mg Modified-Release Tablets

Trial Locations (33)

17033

KalVista Investigative Site, Hershey

20815

KalVista Investigative Site, Chevy Chase

33620

KalVista Investigative Site, Tampa

35294

KalVista Investigative Site, Birmingham

45231

KalVista Investigative Site, Cincinnati

63110

KalVista Investigative Site, St Louis

75390

KalVista Investigative Site, Dallas

80112

KalVista Investigative Site, Centennial

85251

KalVista Investigative Site, Scottsdale

90404

KalVista Investigative Site, Santa Monica

92093

KalVista Investigative Site, La Jolla

99204

KalVista Investigative Site, Spokane

02114

KalVista Investigative Site, Boston

Unknown

KalVista Investigative Site, Campbelltown

KalVista Investigative Site, Sofia

KalVista Investigative Site, North York

KalVista Investigative Site, Brno

KalVista Investigative Site, Prague

KalVista Investigative Site, Grenoble

KalVista Investigative Site, Paris

KalVista Investigative Site, Mainz

KalVista Investigative Site, Berlin

KalVista Investigative Site, Frankfurt am Main

KalVista Investigative Site, Budapest

KalVista Investigative Site, Milan

KalVista Investigative Site, Padua

KalVista Investigative Site, Grafton

KalVista Investigative Site, Skopje

KalVista Investigative Site, San Juan

KalVista Investigative Site, Birmingham

KalVista Investigative Site, Leeds

KalVista Investigative Site, London

KalVista Investigative Site, Newcastle upon Tyne